NICE has included the new antibiotic Fetcroja (cefiderocol) in its pilot reimbursement

Gloran-negative bacteria generally refer to bacteria with a red color reaction.
pathogenic ability of terrain-negative bacteria is usually associated with the composition of its cell walls and, more specifically, its lipid polysaccharide layer.
in the human body, lipid polysaccharides can stimulate an innate immune system characterized by cytocytocin production and immune system resuming.
because of the fat polysaccharides in the cell walls of Glorene-negative bacteria, most or older antibiotics are not effective in suppressing these bacteria.
, a new antibiotic from shionogi, a pharmaceutical company, has been selected by the National Institute for Health and Care Excellence (NICE) in the UK to be included in the pilot reimbursement.
Fetcroja has been earmarked to treat infections caused by adult Glominic-negative bacteria, including those caused by carbon-resistant E. coli, copper-green protons, Baumann's Bacillus and Streptococcus malt.
, head of global market access at Shionogi, said: "We are pleased that NICE recognises the important role of the new antibiotic Fetcroja (cefiderocol) in antimicrobial resistance."
。